Study ID: Janssen SHINE PCI-32765MCL3002

A Randomized, Double-Blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects with Newly Diagnosed Mantle Cell Lymphoma


Participants in this study have been diagnosed with Mantle Cell Lymphoma (MCL). Mantle Cell Lymphoma is a type of cancer that affects the lymphatic system. The lymphatic system helps to fight infections and disease. Ibrutinib is known as a ¿Bruton¿s Tyrosine Kinase (BTK) inhibitor¿. This is an experimental drug that blocks an enzyme that affects how the lymphocytes grow and survive. Blocking this enzyme is an important mechanism in killing cancer cells. In this study, Ibrutinib is tested to see if it may be useful in patients with MCL, who have not been treated previously for this disease. The purpose of this study is to compare the effects (both good and bad) of Ibrutinib when it is given with Bendamustine (known as Treanda) and Rituximab (known as Rituxan) to Bendamustine and Rituximab alone.

Fargo Region
Principal Investigator:
Ammar Alzoubi, MD;Rebecca Kreis
NHL (Non-Hodgkins Lymphoma)
Phase III


Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list